The CD40 agonistic antibody has mutations (indicated by stars) in the heavy chains that increase its specific binding to FcγRIIB and minimize its binding to FcγRIIA. The unaltered CD40 antibody interacts with cells with both types of Fc receptors (such as macrophages) through the Fc receptor and antigen-presenting dendritic cells through CD40 to stimulate a weak anti-tumor response. The mutated antibody interacts with cells with abundant FcγRIIB (such as B cells) and stimulates a strong anti-tumor response. [Credit Heather McDonald]
Read more at
N. R. Gough, Optimizing anti-tumor therapies with engineered antibodies. BioSerendipity (18 September 2018) https://www.bioserendipity.com/optimizing-anti-tumor-therapies-with-engineered-antibodies/